Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The IRE1α/XBP1 pathway sustains cytokine responses of group 3 innate lymphoid cells in inflammatory bowel disease
Siyan Cao, … , Parakkal Deepak, Marco Colonna
Siyan Cao, … , Parakkal Deepak, Marco Colonna
Published May 9, 2024
Citation Information: J Clin Invest. 2024;134(13):e174198. https://doi.org/10.1172/JCI174198.
View: Text | PDF
Research Article Gastroenterology Immunology Article has an altmetric score of 14

The IRE1α/XBP1 pathway sustains cytokine responses of group 3 innate lymphoid cells in inflammatory bowel disease

  • Text
  • PDF
Abstract

Group 3 innate lymphoid cells (ILC3s) are key players in intestinal homeostasis. ER stress is linked to inflammatory bowel disease (IBD). Here, we used cell culture, mouse models, and human specimens to determine whether ER stress in ILC3s affects IBD pathophysiology. We show that mouse intestinal ILC3s exhibited a 24-hour rhythmic expression pattern of the master ER stress response regulator inositol-requiring kinase 1α/X-box–binding protein 1 (IRE1α/XBP1). Proinflammatory cytokine IL-23 selectively stimulated IRE1α/XBP1 in mouse ILC3s through mitochondrial ROS (mtROS). IRE1α/XBP1 was activated in ILC3s from mice exposed to experimental colitis and in inflamed human IBD specimens. Mice with Ire1α deletion in ILC3s (Ire1αΔRorc) showed reduced expression of the ER stress response and cytokine genes including Il22 in ILC3s and were highly vulnerable to infections and colitis. Administration of IL-22 counteracted their colitis susceptibility. In human ILC3s, IRE1 inhibitors suppressed cytokine production, which was upregulated by an IRE1 activator. Moreover, the frequencies of intestinal XBP1s+ ILC3s in patients with Crohn’s disease before administration of ustekinumab, an anti-IL-12/IL-23 antibody, positively correlated with the response to treatment. We demonstrate that a noncanonical mtROS-IRE1α/XBP1 pathway augmented cytokine production by ILC3s and identify XBP1s+ ILC3s as a potential biomarker for predicting the response to anti–IL-23 therapies in IBD.

Authors

Siyan Cao, Jose L. Fachi, Kaiming Ma, Alina Ulezko Antonova, Qianli Wang, Zhangying Cai, Randal J. Kaufman, Matthew A. Ciorba, Parakkal Deepak, Marco Colonna

×

Figure 7

IRE1 modulators orchestrate cytokine production in human ILC3s; intestinal XBP1+ ILC3s positively correlate with response to ustekinumab in patients with CD.

Options: View larger image (or click on image) Download as PowerPoint
IRE1 modulators orchestrate cytokine production in human ILC3s; intestin...
(A) Expression of ERN1 (IRE1A) in colonic ILC3s from healthy controls and from inflamed and noninflamed tissues of patients with UC. (B) Expression of UPR genes in colonic ILC3s from healthy controls and from inflamed and noninflamed tissues of patients with UC. (C–F) ILC3s were sort-purified from colonic biopsies collected from healthy individuals, treated as noted with IL-23 (10 ng/mL in C and D; 0.1 ng/mL in E and F), 10 μM 4μ8C, 1 μM KIRA6, or 10 μM IXA4 for 10 hours (with GolgiPlug for the last 4 hours). Intracellular XBP1s (C and E) and IL-22 (D and F) levels were measured by flow cytometry (n = 5–6). Representative plots and the percentage of IL-22+ ILC3s in each sample are shown. (G) ILC3s were isolated from inflamed mucosal biopsies collected from patients with CD before starting ustekinumab. ILC3 markers and intracellular XBP1s were detected by flow cytometry. Representative plots are shown on the top, and the percentage of XBP1s+ ILC3s in each sample shown on the bottom (total n = 28). Error bars indicate the SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 2-tailed Student t test (E–G) or 1-way ANOVA with Tukey’s multiple-comparison test (A, C, and D).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 23 X users
On 1 Facebook pages
17 readers on Mendeley
See more details